These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 12899246

  • 1. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
    [Abstract] [Full Text] [Related]

  • 2. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV, Ji M, Bloomer WD.
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
    [Abstract] [Full Text] [Related]

  • 3. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2002 Aug; 13(1):47-54. PubMed ID: 12201674
    [Abstract] [Full Text] [Related]

  • 4. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 1997 Aug; 9(5):249-57. PubMed ID: 9306432
    [Abstract] [Full Text] [Related]

  • 5. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):775-9. PubMed ID: 9845094
    [Abstract] [Full Text] [Related]

  • 6. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV, Ji X, Bloomer WD.
    J Exp Ther Oncol; 2006 Nov 01; 5(4):261-72. PubMed ID: 17024967
    [Abstract] [Full Text] [Related]

  • 7. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
    Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG.
    J Exp Ther Oncol; 2002 Nov 01; 2(5):298-305. PubMed ID: 12416033
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD.
    Cancer Chemother Pharmacol; 2002 Oct 01; 50(4):291-8. PubMed ID: 12357303
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
    Papadopoulou MV, Ji X, Bloomer WD.
    Anticancer Res; 2005 Oct 01; 25(3B):2161-70. PubMed ID: 16158959
    [Abstract] [Full Text] [Related]

  • 10. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 1996 Oct 01; 8(10-11):425-34. PubMed ID: 9114435
    [Abstract] [Full Text] [Related]

  • 11. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Oct 01; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.
    Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):501-8. PubMed ID: 12451478
    [Abstract] [Full Text] [Related]

  • 13. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Basic Clin Pharmacol Toxicol; 2011 Jun 01; 108(6):396-9. PubMed ID: 21205223
    [Abstract] [Full Text] [Related]

  • 14. Acute in vivo resistance in high-dose therapy.
    Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E.
    Clin Cancer Res; 1998 Feb 01; 4(2):483-91. PubMed ID: 9516940
    [Abstract] [Full Text] [Related]

  • 15. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer: mechanistic studies. II.
    Papadopoulou MV, Rosenzweig HS, Ji M, Khan SH, Bloomer WD.
    Oncol Res; 1998 Feb 01; 10(3):163-73. PubMed ID: 9700727
    [Abstract] [Full Text] [Related]

  • 16. Effect of Paclitaxel on Antitumor Activity of Cyclophosphamide: Study on Two Transplanted Tumors in Mice.
    Kaledin VI, Nikolin VP, Popova NA, Pyshnaya IA, Bogdanova LA, Morozkova TS.
    Bull Exp Biol Med; 2015 Nov 01; 160(1):81-3. PubMed ID: 26597686
    [Abstract] [Full Text] [Related]

  • 17. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
    Fujimoto S, Chikazawa H.
    Jpn J Cancer Res; 1998 Dec 01; 89(12):1343-51. PubMed ID: 10081496
    [Abstract] [Full Text] [Related]

  • 18. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E.
    Cancer Res; 1991 Feb 15; 51(4):1086-91. PubMed ID: 1825474
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [Abstract] [Full Text] [Related]

  • 20. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
    Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E.
    Semin Oncol; 1990 Feb 15; 17(1 Suppl 3):18-32. PubMed ID: 2106164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.